High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients

OBJECTIVE: Severely ill COVID-19 patients may end in acute respiratory distress syndrome (ARDS) and multi-organ failure. Some of them develop a systemic hyperinflammatory state produced by the massive release of inflammatory agents, known as cytokine storm syndrome (CSS). Inhibition of IL-1 by Anaki...

Descripción completa

Detalles Bibliográficos
Autores principales: Iglesias-Julián, Enrique, López-Veloso, María, de-la-Torre-Ferrera, Noelia, Barraza-Vengoechea, Julio Cesar, Delgado-López, Pedro David, Colazo-Burlato, María, Ubeira-Iglesias, Marta, Montero-Baladía, Miguel, Lorenzo-Martín, Andrés, Minguito-de-la-Iglesia, Javier, García-Muñoz, Juan Pablo, Sanllorente-Sebastián, Rodrigo, Vicente-González, Blanca, Alemán-Alemán, Ana, Buzón-Martín, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439828/
https://www.ncbi.nlm.nih.gov/pubmed/32843231
http://dx.doi.org/10.1016/j.jaut.2020.102537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439828/
https://www.ncbi.nlm.nih.gov/pubmed/32843231
http://dx.doi.org/10.1016/j.jaut.2020.102537

Ejemplares similares